Literature DB >> 24198403

Promyelocytic leukemia protein is a cell-intrinsic factor inhibiting parvovirus DNA replication.

Angela M Mitchell1, Matthew L Hirsch, Chengwen Li, R Jude Samulski.   

Abstract

Tripartite motif proteins are important viral restriction factors and affect processes ranging from uncoating to transcription to immune signaling. Specifically, the promyelocytic leukemia protein (TRIM19; also called PML) is a viral restriction factor inhibiting processes from uncoating to transcription to cell survival. Here we investigated PML's effect on adeno-associated virus (AAV), a parvovirus used for gene delivery. Although dependovirus (AAV) and autonomous parvovirus (minute virus of mice) replication centers can colocalize with PML, PML's functional effect on parvoviruses is unknown. Using PML knockout mice, we determined that PML knockout enhances recombinant AAV2 (rAAV2) transduction at a range of vector doses in both male and female mice. In fact, male and female PML knockout mice exhibited up to 56-fold and 28-fold increases in transduction, respectively. PML inhibited several rAAV serotypes, suggesting a conserved mechanism, and organ specificity correlated with PML expression. Mechanistically, PML inhibited rAAV second-strand DNA synthesis, precluding inhibition of self-complementary rAAV, and did not affect the prior steps in transduction. Furthermore, we confirmed the effect of human PML on rAAV transduction through small interfering RNA (siRNA)-mediated knockdown in HuH7 cells and determined that the highest level of inhibition was due to effects of PML isoform II (PMLII). Overexpression of PMLII resulted in inhibition of second-strand synthesis, vector production, and genome replication. Moreover, wild-type AAV2 production and infectivity were also inhibited by PMLII, demonstrating a PML interaction with wild-type AAV. These data have important implications for AAV-mediated gene therapy. Additionally, PMLII inhibition of AAV second-strand synthesis and replication, which are processes necessary for all parvoviruses, suggests implications for replication of other parvoviruses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24198403      PMCID: PMC3911643          DOI: 10.1128/JVI.02922-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Dynamics of component exchange at PML nuclear bodies.

Authors:  Stefanie Weidtkamp-Peters; Thorsten Lenser; Dmitri Negorev; Norman Gerstner; Thomas G Hofmann; Georg Schwanitz; Christian Hoischen; Gerd Maul; Peter Dittrich; Peter Hemmerich
Journal:  J Cell Sci       Date:  2008-07-29       Impact factor: 5.285

2.  Characterization of endogenous human promyelocytic leukemia isoforms.

Authors:  Wilfried Condemine; Yuki Takahashi; Jun Zhu; Francine Puvion-Dutilleul; Sarah Guegan; Anne Janin; Hugues de Thé
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

3.  Production and characterization of adeno-associated viral vectors.

Authors:  Joshua C Grieger; Vivian W Choi; R Jude Samulski
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

4.  Adenovirus type 5 E4 Orf3 protein targets promyelocytic leukaemia (PML) protein nuclear domains for disruption via a sequence in PML isoform II that is predicted as a protein interaction site by bioinformatic analysis.

Authors:  Keith N Leppard; Edward Emmott; Marc S Cortese; Tina Rich
Journal:  J Gen Virol       Date:  2009-01       Impact factor: 3.891

5.  Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus.

Authors:  Jarrod S Johnson; R Jude Samulski
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

6.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection.

Authors:  Carmela Zincarelli; Stephen Soltys; Giuseppe Rengo; Joseph E Rabinowitz
Journal:  Mol Ther       Date:  2008-04-15       Impact factor: 11.454

7.  Purification of host cell enzymes involved in adeno-associated virus DNA replication.

Authors:  Kevin Nash; Weijun Chen; William F McDonald; Xiaohuai Zhou; Nicholas Muzyczka
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

8.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.

Authors:  Catherine S Manno; Glenn F Pierce; Valder R Arruda; Bertil Glader; Margaret Ragni; John J Rasko; John Rasko; Margareth C Ozelo; Keith Hoots; Philip Blatt; Barbara Konkle; Michael Dake; Robin Kaye; Mahmood Razavi; Albert Zajko; James Zehnder; Pradip K Rustagi; Hiroyuki Nakai; Amy Chew; Debra Leonard; J Fraser Wright; Ruth R Lessard; Jürg M Sommer; Michael Tigges; Denise Sabatino; Alvin Luk; Haiyan Jiang; Federico Mingozzi; Linda Couto; Hildegund C Ertl; Katherine A High; Mark A Kay
Journal:  Nat Med       Date:  2006-02-12       Impact factor: 53.440

9.  Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100.

Authors:  Roger D Everett; Carlos Parada; Philippe Gripon; Hüseyin Sirma; Anne Orr
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

10.  A role for cytoplasmic PML in cellular resistance to viral infection.

Authors:  Beth A McNally; Joanne Trgovcich; Gerd G Maul; Yang Liu; Pan Zheng
Journal:  PLoS One       Date:  2008-05-28       Impact factor: 3.240

View more
  13 in total

Review 1.  Underlying mechanisms of HIV-1 latency.

Authors:  Bizhan Romani; Elham Allahbakhshi
Journal:  Virus Genes       Date:  2017-03-03       Impact factor: 2.332

Review 2.  Emerging Role of PML Nuclear Bodies in Innate Immune Signaling.

Authors:  Myriam Scherer; Thomas Stamminger
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

Review 3.  Diverse mechanisms evolved by DNA viruses to inhibit early host defenses.

Authors:  Marni S Crow; Krystal K Lum; Xinlei Sheng; Bokai Song; Ileana M Cristea
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-09-21       Impact factor: 8.250

4.  Recombinant adeno-associated virus vectors in the treatment of rare diseases.

Authors:  Eric Hastie; R Jude Samulski
Journal:  Expert Opin Orphan Drugs       Date:  2015-05-15       Impact factor: 0.694

5.  An Adenovirus DNA Replication Factor, but Not Incoming Genome Complexes, Targets PML Nuclear Bodies.

Authors:  Tetsuro Komatsu; Kyosuke Nagata; Harald Wodrich
Journal:  J Virol       Date:  2015-11-25       Impact factor: 5.103

6.  Promyelocytic leukemia protein isoform II inhibits infection by human adenovirus type 5 through effects on HSP70 and the interferon response.

Authors:  Zeenah Atwan; Jordan Wright; Andrew Woodman; Keith N Leppard
Journal:  J Gen Virol       Date:  2016-05-23       Impact factor: 3.891

7.  The SUMOylation Pathway Restricts Gene Transduction by Adeno-Associated Viruses.

Authors:  Christina Hölscher; Florian Sonntag; Katharina Henrich; Qingxin Chen; Jürgen Beneke; Petr Matula; Karl Rohr; Lars Kaderali; Nina Beil; Holger Erfle; Jürgen A Kleinschmidt; Martin Müller
Journal:  PLoS Pathog       Date:  2015-12-01       Impact factor: 6.823

8.  Gene Knockout Shows That PML (TRIM19) Does Not Restrict the Early Stages of HIV-1 Infection in Human Cell Lines.

Authors:  Nasser Masroori; Pearl Cherry; Natacha Merindol; Jia-Xin Li; Caroline Dufour; Lina Poulain; Mélodie B Plourde; Lionel Berthoux
Journal:  mSphere       Date:  2017-06-21       Impact factor: 4.389

9.  An siRNA Screen Identifies the U2 snRNP Spliceosome as a Host Restriction Factor for Recombinant Adeno-associated Viruses.

Authors:  Claire A Schreiber; Toshie Sakuma; Yoshihiro Izumiya; Sara J Holditch; Raymond D Hickey; Robert K Bressin; Upamanyu Basu; Kazunori Koide; Aravind Asokan; Yasuhiro Ikeda
Journal:  PLoS Pathog       Date:  2015-08-05       Impact factor: 6.823

10.  PML/TRIM19-Dependent Inhibition of Retroviral Reverse-Transcription by Daxx.

Authors:  Jacques Dutrieux; Ghizlane Maarifi; Débora M Portilho; Nathalie J Arhel; Mounira K Chelbi-Alix; Sébastien Nisole
Journal:  PLoS Pathog       Date:  2015-11-13       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.